Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Filings indexed 383 across all filing types
Latest filing 2023-02-14 Regulatory Filings
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a corporate update related to a conference presentation, commercial launch information, financial expectations, regulatory updates, and clinical trial progress. It does not contain detailed financial statements or comprehensive financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like earnings release or management reports since it is more of a corporate update and regulatory disclosure. Given the nature of Form 8-K filings and the content, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-02-14 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-13 English
SCHEDULE 13G
Major Shareholding Notification
2023-02-09 English
FORM 5 SUBMISSION
Director's Dealing
2023-01-11 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-11 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.